Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

A federal judge ordered the tech giant to let rival app stores onto its Android smartphone platform, adding to its growing ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

After a monster month of spot play, pharmaceutical giant Pfizer had a dramatic drop in the Media Monitors "Spot Ten" list for ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...